Primary Site >> Colorectal Cancer
Gene >> MED12
|
|
|
|
|---|---|---|---|
|
Ref: Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. PMID: 22532225 Ref: Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. PMID: 23132392 Ref: MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. PMID: 23178117 |
Ref: Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. PMID: 24170544 Ref: Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas. PMID: 24980722 |
Ref: RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. PMID: 26350096 |
Ref: MED12 is recurrently mutated in Middle Eastern colorectal cancer. PMID: 28183795 Ref: Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19. PMID: 29440396 Ref: Depletion of Mediator Kinase Module Subunits Represses Superenhancer-Associated Genes in Colon Cancer Cells. PMID: 29507187 Ref: Multilayered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/betacatenin signaling activation (Review). PMID: 29786110 |